USANA Health Sciences Inc

USANA maintains a strong liquidity position with $158.4 million in cash and equivalents, representing 21.3% of total assets, and a current ratio of 2.24, well above the industry median of 1.5. The company's low debt-to-equity ratio of 0.03 reflects a conservative capital structure, with long-term debt of $14 million compared to total equity of $533.1 million. Free cash flow of $30.8 million in the latest period supports operational flexibility and potential for shareholder returns. Profitability metrics show mixed performance. Return on equity (ROE) of 2.02% and return on assets (ROA) of 1.45% lag behind the industry median ROE of 5.2% and ROA of 3.1%. Operating income of $37.4 million and net income of $10.8 million represent 4.04% and 1.17% of revenue, respectively, below the industry median operating margin of 6.8%. Gross profit of $724.4 million, or 78.3% of revenue, is in line with the industry median gross margin of 77.5%. Geographically, USANA derives 62% of revenue from North America, 23% from Asia-Pacific, and 15% from Latin America, according to disclosed segments. The company's direct sales model is heavily dependent on distributor networks, with no single customer accounting for more than 10% of revenue. Outlook for FY2024 shows revenue growth of 1.5% to $938.7 million, with analysts projecting EPS of $1.95 compared to actual $1.93. For FY2025, revenue is expected to increase by 3.2% to $967.3 million, with EPS estimates rising to $2.05. These projections are supported by a 1.4% year-over-year revenue increase in the latest period. Risk assessment indicates low liquidity and dilution risk, with no immediate filing-based flags detected. The company's low debt load and strong cash position reduce financial stress exposure. However, the direct sales model introduces volatility from distributor turnover and regulatory scrutiny in international markets. Recent 10-K filings disclose ongoing compliance with dietary supplement regulations in the U.S. and Canada, and no material legal proceedings. The company also announced a new product line in Q2 2024, targeting the plant-based nutrition segment.